In hormone receptor-positive ( HR ) + disease , only high-Ki-@ tumors ( @ % ) derived significant benefit from taxane-based therapy : hazard ratio = @ ( @ % CI @-@ @ ) for EC-Doc versus FEC ( test for interaction ; P = @ ) .